Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Imatinib- and Sunitinib-Resistant Gastrointestinal Stromal Tumor
NCT00265798Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2005
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in gastrointestinal stromal tumor (GIST), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate up to 5 years. Started Sep 2005; status: active, not recruiting.
02
Drugs
sorafenib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT00265798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00265798.